

RDB-CAM

STAMP TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

U.S. Patent No. 5,447,851 for Bruce A. Beutler et al.
Reexam Serial No. 90/004389 Group Art Unit: 1814
Reexam Filing Date: 3/25/97 Examiner: K. Carlson
For: DNA ENCODING A CHIMERIC POLYPEPTIDE COMPRISING
THE EXTRACELLULAR DOMAIN OF THE TNF RECEPTOR
FUSED TO IGG, VECTORS AND HOST CELLS

RECEIVED MAR 6 1998

1. Revocation of Power of Attorney and Grant of New Power of Attorney;
2. Associate Power of Attorney;
3. Copy of Assignment with attachment.

Dated: March 6, 1998

Case Ref.: 03260.0010

Atty: L.A. McDonell/D. Brady at MD#662

n/d/d



DSD/PTCS

1998-MAR-9, PM 3:33

RECEIVED

STAMP TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

U.S. Patent No. 5,447,851 for Bruce A. Beutler et al.
Reexam Serial No. 90/004589 Group Art Unit: 1814
Reexam Filing Date: 3/25/97 Examiner: K. Carlson
For: DNA ENCODING A CHIMERIC POLYPEPTIDE COMPRISING
THE EXTRACELLULAR DOMAIN OF THE TNF RECEPTOR
FUSED TO IGG, VECTORS AND HOST CELLS

RECEIVED MAR 6 1998

1. Assignment Recordation Form PTO-1595;
2. Assignment Agreement with attachment A;
3. Check for \$40.00 representing recordation fee

Dated: March 6, 1998

Case Ref.: 03260.0010

Atty: L.A. McDonell/D. Brady at MD#662

n/d/d



DICED
3/9/98

JOE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent of:)
)
Bruce A. Beutler et al.)
)
Patent No. 5,447,851) Group Art Unit: 1814
(Reexam Serial No. 90/004589)
)
Reexamination Filing Date: 3/25/97) Examiner: K. Carlson
)
For: DNA ENCODING A CHIMERIC POLY-)
PEPTIDE COMPRISING THE EXTRA-)
CELLULAR DOMAIN OF THE TNF)
RECEPTOR FUSED TO IGG, VECTORS)
AND HOST CELLS)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

**REVOCATION OF POWER OF ATTORNEY
AND GRANT OF NEW POWER OF ATTORNEY**

Assignee, IMMUNEX CORPORATION, hereby revokes all previous powers of attorney given in the above-identified patent under reexamination, including the Power of Attorney to ARNOLD, WHITE & DURKEE, and members of said firm, and hereby grant power of attorney to FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P., Reg. No. 22,540, Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Hefter, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 26,691; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Reilley, Reg. No. 27,932; Allen M. Sokal, Reg. No. 26,695; Robert D. Bajefsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Irving, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,165; Thomas W. Winland,

RECEIVED
1998 APR -9 PM 3:33
USPTO/PTCS

Bruce A. Beutler
U.S. Patent No. 5,447,851

Attorney Docket No.: 03260-0010

Reg. No. 27,605; Basil J. Lewis, Reg. No. 28,818; Martin I. Fuchs, Reg. No. 28,508; E. Robert Yoches, Reg. No. 30,120; Barry W. Graham, Reg. No. 29,924; Susan Haberman Griffen, Reg. No. 30,907; Richard B. Racine, Reg. No. 30,415; Thomas H. Jenkins, Reg. No. 30,857; Robert E. Converse, Jr., Reg. No. 27,432; Clair X. Mullen, Jr., Reg. No. 20,348; Christopher P. Foley, Reg. No. 31,354; John C. Paul, Reg. No. 30,413; David M. Kelly, Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,146; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr., Reg. No. 31,738; Steven M. Anzalone, Reg. No. 32,095; Jean B. Fordis, Reg. No. 32,984; Barbara C. McCurdy, Reg. No. 32,120; James K. Hammond, Reg. No. 31,964; Richard V. Burgujian, Reg. No. 31,744; J. Michael Jakes, Reg. No. 32,824; Thomas W. Banks, Reg. No. 32,719; M. Paul Barkcr, Reg. No. 32,013; Bryan C. Diner, Reg. No. 32,409; Christopher P. Isaac, Reg. No. 32,616; Andrew C. Sonu, Reg. No. 33,457; Dirk D. Thomas, Reg. No. 32,600; David S. Forman, Reg. No. 33,694; Vincent P. Kovalick, Reg. No. 32,867; and Leslie A. McDonell, Reg. No. 34,874; both jointly and separately as their attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and to receive the Letters Patent.

Please send all future correspondence concerning this application using Attorney Docket No. 03260-0010 to Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., at the following address:

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
1300 I Street, N.W.
Washington, D.C. 20005-3315

RECEIVED
1998 APR -9 PM 3:33
DSD/PTCS

Assignee elects, under 37 C.F.R. § 3.71 to prosecute the patent under reexamination to the exclusion of the inventors.

IMMUNEX CORPORATION, duly organized under the laws of Delaware and Washington, and having its principal place of business at 51 University Street, Seattle Washington 98101-2936, represents that it is the only assignee of the entire right, title and interest in and to the above-identified application by assignment duly filed for recording in the United States Patent and Trademark Office concurrently herewith. Assignee, IMMUNEX

APR 08 '98 16:25 FR FINNEGAN HENDERSON 202 408 4400 TO 17033085257

P.07

Bruce A. Beutler et al.
U.S. Patent No. 5,447,851

Attorney Docket No.: 03260-0010

CORPORATION, pursuant to 37 C.F.R. § 3.73, further represents that the evidentiary documents establishing the assignment have been viewed and certify, that to the best of assignee's knowledge and belief, title to the above-identified patent under reexamination is to assignee, who is submitting this Revocation of Power of Attorney and Power of Attorney.

Date: 3.5.98

By: Scott G. Hallquist

Scott G. Hallquist

Senior Vice President and General Counsel

IMMUNEX CORPORATION

RECEIVED
098 APR -9 PM 3:33
DSD/PTCS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent of:

Bruce A. Beutler et al.,

Patent No. 5,447,851
(Reexam Serial No. 90/004589)

Reexamination Filing Date: 3/25/97

For: DNA ENCODING A CHIMERIC
POLYPEPTIDE COMPRISING THE
EXTRACELLULAR DOMAIN OF
THE TNF RECEPTOR FUSED TO
IGG, VECTORS AND HOST CELLS

Group Art No. 1814

Examiner: K. Carlson

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
1998 APR -9 PM 3:33
DSO/PICS

ASSOCIATE POWER OF ATTORNEY

In addition to those attorneys listed in the REVOCATION OF POWER OF ATTORNEY AND GRANT OF NEW POWER OF ATTORNEY filed herewith, the power to prosecute and transact all business in the U.S. Patent and Trademark Office connected with the above-referenced reexamination application is hereby granted to the following attorneys and agents:

Scott G. Hallquist
Registration No. 30,641

Christopher L. Wight
Registration No. 31,680

Stephen L. Malaska
Registration No. 32,655

Michael K. Kirschner
Registration No. 34,851

Janis C. Henry
Registration No. 34,347

Kathryn A. Anderson
Registration No. 32,172

Patricia Anne Perkins
Registration No. 34,693

Respectfully submitted,
IMMUNEX CORPORATION

Date: 3.5.98

By: Scott G. Hallquist
Scott G. Hallquist
Senior Vice President and General Counsel
Registration No. 30,641

ASSIGNMENT

WHEREAS, the Board of Regents, The University of Texas System, having a place of business at 201 West Seventh Street, Austin, Texas 78701 [hereinafter referred to as "the Board of Regents"], owns, by assignment, all right, title and interest in U.S. Patent No. 5,447,851, entitled DNA ENCODING A CHIMERIC POLYPEPTIDE COMPRISING THE EXTRACELLULAR DOMAIN OF TNF RECEPTOR FUSED TO IGG, VECTORS, AND HOST CELLS and any invention claimed therein; and

WHEREAS, Immunex Corporation, a corporation of Washington having a place of business at 51 University Street, Seattle, Washington 98101 (hereinafter referred to as "Immunex"), desires to own Regents' entire right, title, and interest in and to the invention, in all countries throughout the world, and in and to United States Letters Patent No. 5,447,851;


NOW THEREFORE, be it known that, for good and valuable consideration, receipt of which is hereby acknowledged, the Board of Regents hereby sells, assigns, transfers and sets over to Immunex, its lawful successors and assigns, the Board of Regents' entire right, title, and interest in and to U.S. Patent No. 5,447,851, the invention claimed therein, all reissues, reexaminations and extensions thereof and all rights to claim priority on the basis of such application. The Board of Regents hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States to issue all Letters Patent for this invention to Immunex, its successors and assigns, in accordance with the terms of this Assignment. The grant made hereby is subject to the provisions of the Assignment Agreement executed by the Board of Regents concurrently with this Assignment;

AND, THE BOARD OF REGENTS HEREBY further represents, warrants and covenants that the Board of Regents has the full right to convey the interest assigned by this Assignment, the Board of Regents will take all action and execute all documents necessary to perfect the interest assigned hereby, and the Board of Regents has not executed and will not execute any agreement in conflict with this Assignment.


RECEIVED
1998 APR -9 PM 3:33
DEPT/PTCS

IN TESTIMONY WHEREOF, each party has caused its authorized representative to execute this Assignment.

The Board of Regents, The University
of Texas System

By: 
Name: Ray Farabee
Title: Vice Chancellor and General Counsel,
The Board of Regents, The University
of Texas System
Date: 1/21/98

Immunex Corporation

By: 
Name: Edward V. Fritzky
Title: Chief Executive Officer
Date: 1/9/98

RECEIVED
1998 APR -9 PM 3:33
DSB/PTCS